Business · 27/10/20261 min read
Teva acquires worldwide rights to BXCL501, further expanding innovative neuroscience pipeline
Summary
Teva acquires worldwide rights to BXCL501, expanding its neuroscience pipeline with a potential home treatment for agitation currently under FDA review.
Original source language: GlobeNewswire — Mergers and AcquisitionsOpen original release →